Related Experiment Video
Updated: Feb 26, 2026

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model
Published on: September 4, 2017
Megalencephalic leukoencephalopathy with cysts: the Glialcam-null mouse model
Marianna Bugiani1,2, Mohit Dubey1,3, Marjolein Breur1
1Department of Pediatrics/Child Neurology Amsterdam Neuroscience VU University Medical Center Amsterdam The Netherlands.
Objective:
Megalencephalic leukoencephalopathy with cysts (MLC) is a genetic infantile-onset disease characterized by macrocephaly and white matter edema due to loss of MLC1 function. Recessive mutations in either MLC1 or GLIALCAM cause the disease. MLC1 is involved in astrocytic volume regulation; GlialCAM ensures the correct membrane localization of MLC1. Their exact role in brain ion-water homeostasis is only partly defined. We characterized Glialcam-null mice for further studies.
Methods:
We investigated the consequences of loss of GlialCAM in Glialcam-null mice and compared GlialCAM developmental expression in mice and men.
Results:
Glialcam-null mice had early-onset megalencephaly and increased brain water content. From 3 weeks, astrocytes were abnormal with swollen processes abutting blood vessels. Concomitantly, progressive white matter vacuolization developed due to intramyelinic edema. Glialcam-null astrocytes showed abolished expression of MLC1, reduced expression of the chloride channel ClC-2 and increased expression and redistribution of the water channel aquaporin4. Expression of other MLC1-interacting proteins and the volume regulated anion channel LRRC8A was unchanged. In mice, GlialCAM expression increased until 3 weeks and then stabilized. In humans, GlialCAM expression was highest in the first 3 years to then decrease and stabilize from approximately 5 years.
Interpretation:
Glialcam-null mice replicate the early stages of the human disease with early-onset intramyelinic edema. The earliest change is astrocytic swelling, further substantiating that a defect in astrocytic volume regulation is the primary cellular defect in MLC. GlialCAM expression affects expression of MLC1, ClC-2 and aquaporin4, indicating that abnormal interplay between these proteins is a disease mechanism in megalencephalic leukoencephalopathy with cysts.
Insights
Megalencephalic leukoencephalopathy with cysts (MLC) is a genetic brain disorder. GlialCAM deficiency in mice causes early-onset edema and astrocyte swelling, mimicking human MLC disease.
Area of Science:
- Neuroscience
- Genetics
- Cell Biology
Background:
- Megalencephalic leukoencephalopathy with cysts (MLC) is a genetic infantile-onset disease.
- It is characterized by macrocephaly and white matter edema due to loss of MLC1 function.
- Recessive mutations in MLC1 or GLIALCAM cause MLC, impacting astrocytic volume regulation and MLC1 localization.
Purpose of the Study:
- To investigate the consequences of GlialCAM loss in Glialcam-null mice.
- To compare GlialCAM developmental expression in mice and humans.
- To elucidate the role of GlialCAM in brain ion-water homeostasis and MLC pathogenesis.
Main Methods:
- Characterization of Glialcam-null mice.
- Analysis of brain water content, astrocyte morphology, and white matter edema.
- Assessment of MLC1, GlialCAM, ClC-2, aquaporin4, and LRRC8A expression in mouse models.
- Comparison of GlialCAM developmental expression in mice and humans.
Main Results:
- Glialcam-null mice exhibited early-onset megalencephaly and increased brain water content.
- Abnormal astrocytes with swollen processes and progressive white matter vacuolization due to intramyelinic edema were observed.
- Glialcam-null astrocytes showed abolished MLC1 expression, reduced ClC-2, and altered aquaporin4 expression and redistribution.
Conclusions:
- Glialcam-null mice replicate early stages of human MLC, with astrocytic swelling as the primary defect.
- GlialCAM influences MLC1, ClC-2, and aquaporin4 expression, indicating their interplay in MLC pathogenesis.
- Understanding GlialCAM's role is crucial for unraveling brain ion-water homeostasis and developing therapeutic strategies for MLC.

